Biosimilar Testing Service

Biosimilar Testing Service Comprehensive Study by Type (Pharmacokinetic Assay, Tiered Immunogenicity Testing, NAb Assays), Application (Pharmaceutical and Biopharmaceutical Companies, Contract research organizations (CROs), Contract development and manufacturing organizations (CDMOs), Academic institutions and research laboratories) Players and Region - Global Market Outlook to 2028

Biosimilar Testing Service Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 16.65%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Biosimilar Testing Service
Biosimilars are highly similar, though not identical, versions of existing biologics (like monoclonal antibodies or insulin). They offer comparable safety and efficacy at a lower cost, increasing patient access to vital treatments. Due to the inherent complexity of biologics, thorough testing is necessary to prove their biosimilarity. This ensures biosimilars perform as effectively and safely as reference products. Biosimilar testing services are crucial for bringing affordable alternatives to expensive biologics to the market. These services help demonstrate the high quality, similarity, and safety of biosimilars compared to their reference products.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR16.65%


The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Biosimilar Testing Service market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

SGS (Switzerland), Merck (Germany), LAB Holdings (China), Antibody Analytics (United States), PPD (United States), Profacgen (Spain), Charles River Laboratories International (United States), Sartoriu (Germany), Pacific BioLabs (United States), Medicilon (China), Eurofins Scientific (France), Kymos Pharma Services (United Kingdom) and Intertek (United Kingdom) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Biosimilar Testing Service market by Type (Pharmacokinetic Assay, Tiered Immunogenicity Testing and NAb Assays), Application (Pharmaceutical and Biopharmaceutical Companies, Contract research organizations (CROs), Contract development and manufacturing organizations (CDMOs) and Academic institutions and research laboratories) and Region.



On the basis of geography, the market of Biosimilar Testing Service has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Advancement in Techniques of Biosimilar Testing Services

Market Growth Drivers:
Rising Demand for Biologics to Address Medical Needs and Growing Demand for the Associated Bioanalytical Testing Services

Challenges:
Lack of Availability of Skilled Labors

Restraints:
Stringent Government Regulations Related to Biosimilar Testing Services

Opportunities:
Increasing R & D Expenditure in Pharmaceutical Companies

Market Leaders and their expansionary development strategies
In November 2023, Antibody Analytics introduces a novel cell-based assay platform. This platform enables more precise evaluation of biosimilar functionality and immunogenicity, enhancing safety and efficacy assessments.
In November 2023, PPD partners with Charles River, this collaboration aims to develop and offer integrated biosimilar development and testing solutions, combining PPD's clinical trial expertise with Charles River's extensive testing capabilities.


Key Target Audience
Developers, Stakeholders, Government Bodies, Suppliers & Distributers, Research Organization and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Pharmacokinetic Assay
  • Tiered Immunogenicity Testing
  • NAb Assays
By Application
  • Pharmaceutical and Biopharmaceutical Companies
  • Contract research organizations (CROs)
  • Contract development and manufacturing organizations (CDMOs)
  • Academic institutions and research laboratories
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for Biologics to Address Medical Needs
      • 3.2.2. Growing Demand for the Associated Bioanalytical Testing Services
    • 3.3. Market Challenges
      • 3.3.1. Lack of Availability of Skilled Labors
    • 3.4. Market Trends
      • 3.4.1. Advancement in Techniques of Biosimilar Testing Services
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Biosimilar Testing Service, by Type, Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Biosimilar Testing Service (Value)
      • 5.2.1. Global Biosimilar Testing Service by: Type (Value)
        • 5.2.1.1. Pharmacokinetic Assay
        • 5.2.1.2. Tiered Immunogenicity Testing
        • 5.2.1.3. NAb Assays
      • 5.2.2. Global Biosimilar Testing Service by: Application (Value)
        • 5.2.2.1. Pharmaceutical and Biopharmaceutical Companies
        • 5.2.2.2. Contract research organizations (CROs)
        • 5.2.2.3. Contract development and manufacturing organizations (CDMOs)
        • 5.2.2.4. Academic institutions and research laboratories
      • 5.2.3. Global Biosimilar Testing Service Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Biosimilar Testing Service: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. SGS (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. LAB Holdings (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Antibody Analytics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PPD (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Profacgen (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Charles River Laboratories International (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sartoriu (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pacific BioLabs (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Medicilon (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eurofins Scientific (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Kymos Pharma Services (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Intertek (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Biosimilar Testing Service Sale, by Type, Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Biosimilar Testing Service (Value)
      • 7.2.1. Global Biosimilar Testing Service by: Type (Value)
        • 7.2.1.1. Pharmacokinetic Assay
        • 7.2.1.2. Tiered Immunogenicity Testing
        • 7.2.1.3. NAb Assays
      • 7.2.2. Global Biosimilar Testing Service by: Application (Value)
        • 7.2.2.1. Pharmaceutical and Biopharmaceutical Companies
        • 7.2.2.2. Contract research organizations (CROs)
        • 7.2.2.3. Contract development and manufacturing organizations (CDMOs)
        • 7.2.2.4. Academic institutions and research laboratories
      • 7.2.3. Global Biosimilar Testing Service Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Biosimilar Testing Service: by Type(USD Million)
  • Table 2. Biosimilar Testing Service Pharmacokinetic Assay , by Region USD Million (2017-2022)
  • Table 3. Biosimilar Testing Service Tiered Immunogenicity Testing , by Region USD Million (2017-2022)
  • Table 4. Biosimilar Testing Service NAb Assays , by Region USD Million (2017-2022)
  • Table 5. Biosimilar Testing Service: by Application(USD Million)
  • Table 6. Biosimilar Testing Service Pharmaceutical and Biopharmaceutical Companies , by Region USD Million (2017-2022)
  • Table 7. Biosimilar Testing Service Contract research organizations (CROs) , by Region USD Million (2017-2022)
  • Table 8. Biosimilar Testing Service Contract development and manufacturing organizations (CDMOs) , by Region USD Million (2017-2022)
  • Table 9. Biosimilar Testing Service Academic institutions and research laboratories , by Region USD Million (2017-2022)
  • Table 10. South America Biosimilar Testing Service, by Country USD Million (2017-2022)
  • Table 11. South America Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 12. South America Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 13. Brazil Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 14. Brazil Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 15. Argentina Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 16. Argentina Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 17. Rest of South America Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 18. Rest of South America Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 19. Asia Pacific Biosimilar Testing Service, by Country USD Million (2017-2022)
  • Table 20. Asia Pacific Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 21. Asia Pacific Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 22. China Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 23. China Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 24. Japan Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 25. Japan Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 26. India Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 27. India Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 28. South Korea Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 29. South Korea Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 30. Taiwan Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 31. Taiwan Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 32. Australia Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 33. Australia Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 36. Europe Biosimilar Testing Service, by Country USD Million (2017-2022)
  • Table 37. Europe Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 38. Europe Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 39. Germany Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 40. Germany Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 41. France Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 42. France Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 43. Italy Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 44. Italy Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 45. United Kingdom Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 46. United Kingdom Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 47. Netherlands Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 48. Netherlands Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 49. Rest of Europe Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 50. Rest of Europe Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 51. MEA Biosimilar Testing Service, by Country USD Million (2017-2022)
  • Table 52. MEA Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 53. MEA Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 54. Middle East Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 55. Middle East Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 56. Africa Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 57. Africa Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 58. North America Biosimilar Testing Service, by Country USD Million (2017-2022)
  • Table 59. North America Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 60. North America Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 61. United States Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 62. United States Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 63. Canada Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 64. Canada Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 65. Mexico Biosimilar Testing Service, by Type USD Million (2017-2022)
  • Table 66. Mexico Biosimilar Testing Service, by Application USD Million (2017-2022)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Biosimilar Testing Service: by Type(USD Million)
  • Table 81. Biosimilar Testing Service Pharmacokinetic Assay , by Region USD Million (2023-2028)
  • Table 82. Biosimilar Testing Service Tiered Immunogenicity Testing , by Region USD Million (2023-2028)
  • Table 83. Biosimilar Testing Service NAb Assays , by Region USD Million (2023-2028)
  • Table 84. Biosimilar Testing Service: by Application(USD Million)
  • Table 85. Biosimilar Testing Service Pharmaceutical and Biopharmaceutical Companies , by Region USD Million (2023-2028)
  • Table 86. Biosimilar Testing Service Contract research organizations (CROs) , by Region USD Million (2023-2028)
  • Table 87. Biosimilar Testing Service Contract development and manufacturing organizations (CDMOs) , by Region USD Million (2023-2028)
  • Table 88. Biosimilar Testing Service Academic institutions and research laboratories , by Region USD Million (2023-2028)
  • Table 89. South America Biosimilar Testing Service, by Country USD Million (2023-2028)
  • Table 90. South America Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 91. South America Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 92. Brazil Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 93. Brazil Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 94. Argentina Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 95. Argentina Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 96. Rest of South America Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 97. Rest of South America Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 98. Asia Pacific Biosimilar Testing Service, by Country USD Million (2023-2028)
  • Table 99. Asia Pacific Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 100. Asia Pacific Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 101. China Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 102. China Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 103. Japan Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 104. Japan Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 105. India Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 106. India Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 107. South Korea Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 108. South Korea Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 109. Taiwan Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 110. Taiwan Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 111. Australia Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 112. Australia Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 113. Rest of Asia-Pacific Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 114. Rest of Asia-Pacific Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 115. Europe Biosimilar Testing Service, by Country USD Million (2023-2028)
  • Table 116. Europe Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 117. Europe Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 118. Germany Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 119. Germany Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 120. France Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 121. France Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 122. Italy Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 123. Italy Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 124. United Kingdom Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 125. United Kingdom Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 126. Netherlands Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 127. Netherlands Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 128. Rest of Europe Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 129. Rest of Europe Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 130. MEA Biosimilar Testing Service, by Country USD Million (2023-2028)
  • Table 131. MEA Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 132. MEA Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 133. Middle East Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 134. Middle East Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 135. Africa Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 136. Africa Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 137. North America Biosimilar Testing Service, by Country USD Million (2023-2028)
  • Table 138. North America Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 139. North America Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 140. United States Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 141. United States Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 142. Canada Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 143. Canada Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 144. Mexico Biosimilar Testing Service, by Type USD Million (2023-2028)
  • Table 145. Mexico Biosimilar Testing Service, by Application USD Million (2023-2028)
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Biosimilar Testing Service: by Type USD Million (2017-2022)
  • Figure 5. Global Biosimilar Testing Service: by Application USD Million (2017-2022)
  • Figure 6. South America Biosimilar Testing Service Share (%), by Country
  • Figure 7. Asia Pacific Biosimilar Testing Service Share (%), by Country
  • Figure 8. Europe Biosimilar Testing Service Share (%), by Country
  • Figure 9. MEA Biosimilar Testing Service Share (%), by Country
  • Figure 10. North America Biosimilar Testing Service Share (%), by Country
  • Figure 11. Global Biosimilar Testing Service share by Players 2022 (%)
  • Figure 12. Global Biosimilar Testing Service share by Players (Top 3) 2022(%)
  • Figure 13. Global Biosimilar Testing Service share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. SGS (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. SGS (Switzerland) Revenue: by Geography 2022
  • Figure 17. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Merck (Germany) Revenue: by Geography 2022
  • Figure 19. LAB Holdings (China) Revenue, Net Income and Gross profit
  • Figure 20. LAB Holdings (China) Revenue: by Geography 2022
  • Figure 21. Antibody Analytics (United States) Revenue, Net Income and Gross profit
  • Figure 22. Antibody Analytics (United States) Revenue: by Geography 2022
  • Figure 23. PPD (United States) Revenue, Net Income and Gross profit
  • Figure 24. PPD (United States) Revenue: by Geography 2022
  • Figure 25. Profacgen (Spain) Revenue, Net Income and Gross profit
  • Figure 26. Profacgen (Spain) Revenue: by Geography 2022
  • Figure 27. Charles River Laboratories International (United States) Revenue, Net Income and Gross profit
  • Figure 28. Charles River Laboratories International (United States) Revenue: by Geography 2022
  • Figure 29. Sartoriu (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Sartoriu (Germany) Revenue: by Geography 2022
  • Figure 31. Pacific BioLabs (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pacific BioLabs (United States) Revenue: by Geography 2022
  • Figure 33. Medicilon (China) Revenue, Net Income and Gross profit
  • Figure 34. Medicilon (China) Revenue: by Geography 2022
  • Figure 35. Eurofins Scientific (France) Revenue, Net Income and Gross profit
  • Figure 36. Eurofins Scientific (France) Revenue: by Geography 2022
  • Figure 37. Kymos Pharma Services (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. Kymos Pharma Services (United Kingdom) Revenue: by Geography 2022
  • Figure 39. Intertek (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Intertek (United Kingdom) Revenue: by Geography 2022
  • Figure 41. Global Biosimilar Testing Service: by Type USD Million (2023-2028)
  • Figure 42. Global Biosimilar Testing Service: by Application USD Million (2023-2028)
  • Figure 43. South America Biosimilar Testing Service Share (%), by Country
  • Figure 44. Asia Pacific Biosimilar Testing Service Share (%), by Country
  • Figure 45. Europe Biosimilar Testing Service Share (%), by Country
  • Figure 46. MEA Biosimilar Testing Service Share (%), by Country
  • Figure 47. North America Biosimilar Testing Service Share (%), by Country
List of companies from research coverage that are profiled in the study
  • SGS (Switzerland)
  • Merck (Germany)
  • LAB Holdings (China)
  • Antibody Analytics (United States)
  • PPD (United States)
  • Profacgen (Spain)
  • Charles River Laboratories International (United States)
  • Sartoriu (Germany)
  • Pacific BioLabs (United States)
  • Medicilon (China)
  • Eurofins Scientific (France)
  • Kymos Pharma Services (United Kingdom)
  • Intertek (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 235 Pages 91 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Biosimilar Testing Service Quantitative research analysis
Biosimilar Testing Service Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as SGS (Switzerland), Merck (Germany), LAB Holdings (China), Antibody Analytics (United States), PPD (United States), Profacgen (Spain), Charles River Laboratories International (United States), Sartoriu (Germany), Pacific BioLabs (United States), Medicilon (China), Eurofins Scientific (France), Kymos Pharma Services (United Kingdom) and Intertek (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Advancement in Techniques of Biosimilar Testing Services" is seen as one of major influencing trends for Biosimilar Testing Service Market during projected period 2022-2028.
The Biosimilar Testing Service market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.
Analysts at AMA estimates Biosimilar Testing Service Market to reach USD10800.0 Million by 2028.

Know More About Biosimilar Testing Service Report?

Have a Query? Click Here

Other Related Reports

Ophthalmic Data Management Systems Comprehensive Study by Deployment Mode (Cloud-Based, Web-Based), Disease Type (Glaucoma, Diabetic Retinopathy, Refractive Error, Age-Related Macular Degeneration, A...
$ 3750
Weight Loss and Diet Management Comprehensive Study by Application (Child, Teen Weight Management, Adult Weight Management, Geriatric Weight Management), Diet Type (Paleo Diet, Low Carb, Keto Diet,...
$ 3800
Orthopedic Procedures Comprehensive Study by Application (Hip, Knee, Spine, Dental, Shoulder, Others), Procedure (Arthroscopy, Joint Reconstruction, Soft Tissue Replacement, Spinal Surgery Procedure,...
$ 3450
Chronic Care Management Solution Comprehensive Study by Type (Medical Reference/Education, Chronic Disease Management, Care Coordination, Others.), Deployment Mode (Cloud-based, On-premise), End-user...
$ 3450
Endocrine Peptides Test Comprehensive Study by Type (Estradiol (E2), Dehydroepiandrosterone sulfate (DHEAS), Human Chorionic Gonadotropin (hCG), Progesterone, Luteinizing Hormone (LH), Thyroid Stimul...
$ 3750
Bifidobacterium Longum Comprehensive Study by Type (0.2g/Piece, 0.25g/Piece), Application (Medicine, Others), Distribution Channel (Online, Offline), Varieties (Sub-acute experimental, Acute) Players...
$ 3500